ELIZABETH SCOTT: Open Payments
NPI 1982106753 · GADSDEN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$605 in 27 payments from 13 companies in 2025. Trend: 2023 $267 · 2024 $323 · 2025 $605
Food & beverage: $605
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 4 | $131 |
| Merz Pharmaceuticals, LLC | 4 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Novartis Pharmaceuticals Corporation | 2 | $57 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| Merck Sharp & Dohme LLC | 2 | $34 |
| TerSera Therapeutics LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
Products named: Hizentra, Xeomin, Kerendia, FRUZAQLA, JARDIANCE, RELISTOR, LUTATHERA, CAPVAXIVE.
Industry payments across AL — which companies pay providers there.
